Loftin, Charles - University of Kentucky

个人简介

Dr. Loftin received a Ph.D. in Toxicology in 1995 from the University of North Carolina at Chapel Hill and a B.S. in Pharmacy in 1989 from Auburn University. Before joining the University of Kentucky, Dr. Loftin was a Research Fellow with the National Institute of Environmental Health Sciences in Research Triangle Park, North Carolina.

研究领域

Dr. Loftin's lab studies the functions of prostanoids, which are lipid mediators formed by most tissues and best known for producing inflammation. Prostanoids are synthesized by the cyclooxygenases that are better known as COX-1 and COX-2. The COX enzymes are targets of nonsteroidal anti-inflammatory drugs, such as aspirin and ibuprofen, and the COX-2-selective inhibitor celecoxib. By utilizing pharmacological inhibitors of the COX enzymes together with mice genetically deficient in either COX-1 or COX-2, Dr. Loftin's lab has identified a variety of different physiological and pathophysiological processes that are dependent on either COX-1 or COX-2. These include prenatal and postnatal vascular development, protection against pathogen-induced atherosclerosis, adipose tissue differentiation, vascular remodeling associated with aortic aneurysm initiation and progression, and vascular smooth muscle cell phenotypic modulation. The goal of this work is to identify targets down-stream of the COX isoforms that will lead to the development of medications with novel therapeutic benefit and which lack the adverse effects of currently available COX inhibitors.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Loftin Charles D. (2016). Microsomal Prostaglandin E Synthase-1 Expression by Aortic Smooth Muscle Cells Attenuates the Differentiated Phenotype. Oestreich J H, Steinhubl S R, Ferraris Suellen Prins, Loftin Charles D, Akers W S. (2014). Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects. Journal of thrombosis and thrombolysis, 38(3), 372-9. Oestreich J H, Steinhubl S R, Ferraris S P, Loftin Charles D, Akers W S. (2014). Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects. J Thromb Thrombolysis, Trivedi D B, Loftin Charles D, Clark J, Myers P, DeGraff L M, Cheng J, Zeldin D C, Langenbach R. (2013). β-Arrestin-2 deficiency attenuates abdominal aortic aneurysm formation in mice. Circ Res, 112((9)), 1219-29. Mukherjee Kamalika, Gitlin Jonathan m, Loftin Charles D. (2012). Effectiveness of Cyclooxygenase-2 Inhibition in Limiting Abdominal Aortic Aneurysm Progression in Mice Correlates With a Differentiated Smooth Muscle Cell Phenotype. Journal of Cardiovascular Pharmacology/Lippincott Williams & Wilkins, 60(6), 520-529. Loftin Charles D, Ghoshal Sarbani. (2012). Cyclooxygenase-2 Inhibition Attenuates Abdominal Aortic Aneurysm Progression in Hyperlipidemic Mice. PLoS One. , 7(11), e44369. Stinchcomb Audra L, Loftin Charles D, Brogden Nicole K, Paudel Kalpana S, Banks Stan L. (2011). Diclofenac Enables Prolonged Delivery of Naltrexone Through Microneedle-Treated Skin. Pharmaceutical Research/Springer, 28(5), 1211-1219. Ghoshal Sarbani, Trivedi Darshini B, Graf Gregory A, Loftin Charles D. (2011). Cyclooxygenase-2 Deficiency Attenuates Adipose Tissue Differentiation and Inflammation in Mice. The Journal of Biological Chemistry/American Society for Biochemistry and Molecular Biology , 286(1), 889-898. Li Tonglei, Loftin Charles D, Mattei Alessandra, Theiss Kathryn L, Long Sihui. (2010). Solid-State Properties of the Cyclooxygenase-1-Selective Inhibitor, SC-560. AAPS PharmSciTech, 11(2), 485-488. Kelso M L, Scheff Stephen William, Pauly James R, Loftin Charles D. (2009). Effects of genetic deficiency of cyclooxygenase-1 or cyclooxygenase-2 on functional and histological outcomes following traumatic brain injury in mice. BMC neuroscience, 10, 108.